The Nellix Endografts And EVAS: The Good, The Bad And The Ugly In A Busy Vascular Center Experience (200 Cases)

Introduction:

• Single center study from July 2013 to September 2016 with retrospective analysis of clinical data
• 200 consecutive pts. treated with EVAS (Nellix)
• Primary focus: Technical success and occurrence of endoleaks

Disclosure

• I have the following potential conflicts of interest to report:
  - Receipt of honoraria and travel support by Endologix

Results:

• Primary technical success: 97.5% (=195/200)
• Technical failure: 2.5% (=5/200)
  - 2 x aneurysm/CIA rupture
  - 2 x persisting rupture/bleeding
  - 1 x endobag rupture intra-arterial polymer leakage
Results I:

- Primary technical success: 97.5% (=195/200)
- Technical failure: 2.5% (=5/200)
  - 2 x aneurysm/CIA rupture
  - 2 x paravasal rupture/bleeding
  - 1 x endobag rupture intra-arterial polymer leakage
- Mean Follow up: 325 d (Median 272, Range 2-1128)
- Endoleaks: 10.5% (WIFU 6.9% vs. OIFU 14.3%)

Results II: Subgroup analysis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Infrarenal</th>
<th>Infra + Iliacs</th>
<th>Juxta-renal</th>
<th>Isolated Iliacs</th>
<th>Repairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>total n (%)</td>
<td>103 (51.5%)</td>
<td>39 (19.5%)</td>
<td>30 (15%)</td>
<td>8 (4%)</td>
<td>7 (3.5%)</td>
</tr>
<tr>
<td>total endoleaks n (%)</td>
<td>8 (7.8%)</td>
<td>3 (7.7%)</td>
<td>2 (6.7%)</td>
<td>1 (12.5%)</td>
<td>3 (42.9%)</td>
</tr>
</tbody>
</table>

WIFU: 6.9% (=7/102) EL
OIFU: 10.0% (=4/40) EL

Results II: Subgroup analysis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Infrarenal</th>
<th>Infra + Iliacs</th>
<th>Juxta-renal</th>
<th>Isolated Iliacs</th>
<th>Repairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>total n (%)</td>
<td>103 (51.5%)</td>
<td>39 (19.5%)</td>
<td>30 (15%)</td>
<td>8 (4%)</td>
<td>7 (3.5%)</td>
</tr>
<tr>
<td>total endoleaks n (%)</td>
<td>8 (7.8%)</td>
<td>3 (7.7%)</td>
<td>2 (6.7%)</td>
<td>1 (12.5%)</td>
<td>3 (42.9%)</td>
</tr>
</tbody>
</table>

38 juxta pts. 31 pts. treated with Chimney-EVAs
Conclusions:

- Seductive device ➔ *Planning is key*

- The good news: very low rate of EL II (2.5%)

- Lowest EL rate in juxta-renal pathologies treated with chimneys (3.2%)

- Flow dynamics ➔ *Proximal landing is key*

- Further studies are needed
Appendix:

Cumulative Endoleak Free Survival Rate

Logrank test (Peto)
p = 0.0003

Within IFU
Outside IFU

At risk:
102           76               45              28               15               5                 1
98            49               21               9                  3       1

Months